DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma.
Saved in:
| Title: | DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma. |
|---|---|
| Authors: | Johnstone CN; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia., Osellame LD; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Cao Z; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia., McDonald AF; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia., Rigopoulos A; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Burvenich IJG; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Wichmann CW; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia., Guo N; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia., Ivashkevich AN; Telix Pharmaceuticals, North Melbourne, Victoria, Australia., Wheatcroft MP; Telix Pharmaceuticals, North Melbourne, Victoria, Australia., Yan EB; Telix Pharmaceuticals, North Melbourne, Victoria, Australia., Zimmermann A; Merck KGaA, Darmstadt, Germany., Zenke FT; EMD Serono, Billerica, Massachusetts; and., Sirrenberg C; Merck KGaA, Darmstadt, Germany., Scott FE; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia., Scott AM; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; andrew.scott@onjcri.org.au.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia.; Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. |
| Source: | Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2025 Mar 03; Vol. 66 (3), pp. 385-390. Date of Electronic Publication: 2025 Mar 03. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Society of Nuclear Medicine Country of Publication: United States NLM ID: 0217410 Publication Model: Electronic Cited Medium: Internet ISSN: 1535-5667 (Electronic) Linking ISSN: 01615505 NLM ISO Abbreviation: J Nucl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 39884775 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of <superscript>177</superscript>Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Johnstone+CN%22">Johnstone CN</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Clinical Pathology, University of Melbourne, Parkville, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Osellame+LD%22">Osellame LD</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Cao+Z%22">Cao Z</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22McDonald+AF%22">McDonald AF</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Rigopoulos+A%22">Rigopoulos A</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Burvenich+IJG%22">Burvenich IJG</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Wichmann+CW%22">Wichmann CW</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Guo+N%22">Guo N</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Ivashkevich+AN%22">Ivashkevich AN</searchLink>; Telix Pharmaceuticals, North Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Wheatcroft+MP%22">Wheatcroft MP</searchLink>; Telix Pharmaceuticals, North Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Yan+EB%22">Yan EB</searchLink>; Telix Pharmaceuticals, North Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Zimmermann+A%22">Zimmermann A</searchLink>; Merck KGaA, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Zenke+FT%22">Zenke FT</searchLink>; EMD Serono, Billerica, Massachusetts; and.<br /><searchLink fieldCode="AU" term="%22Sirrenberg+C%22">Sirrenberg C</searchLink>; Merck KGaA, Darmstadt, Germany.<br /><searchLink fieldCode="AU" term="%22Scott+FE%22">Scott FE</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Scott+AM%22">Scott AM</searchLink>; Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia; andrew.scott@onjcri.org.au.; School of Cancer Medicine, La Trobe University, Bundoora, Victoria, Australia.; Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia.; Department of Medicine, University of Melbourne, Parkville, Victoria, Australia. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220217410%22">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</searchLink> [J Nucl Med] 2025 Mar 03; Vol. 66 (3), pp. 385-390. <i>Date of Electronic Publication: </i>2025 Mar 03. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Research Support, Non-U.S. Gov't – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Society+of+Nuclear+Medicine%22">Society of Nuclear Medicine </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0217410 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1535-5667 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201615505%22">01615505 </searchLink><i>NLM ISO Abbreviation: </i>J Nucl Med <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39884775 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.2967/jnumed.124.268695 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 385 Titles: – TitleFull: DNA-Dependent Protein Kinase Inhibitor Peposertib Enhances Efficacy of 177Lu-Based Radioimmunotherapy in Preclinical Models of Prostate and Renal Cell Carcinoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Johnstone CN – PersonEntity: Name: NameFull: Osellame LD – PersonEntity: Name: NameFull: Cao Z – PersonEntity: Name: NameFull: McDonald AF – PersonEntity: Name: NameFull: Rigopoulos A – PersonEntity: Name: NameFull: Burvenich IJG – PersonEntity: Name: NameFull: Wichmann CW – PersonEntity: Name: NameFull: Guo N – PersonEntity: Name: NameFull: Ivashkevich AN – PersonEntity: Name: NameFull: Wheatcroft MP – PersonEntity: Name: NameFull: Yan EB – PersonEntity: Name: NameFull: Zimmermann A – PersonEntity: Name: NameFull: Zenke FT – PersonEntity: Name: NameFull: Sirrenberg C – PersonEntity: Name: NameFull: Scott FE – PersonEntity: Name: NameFull: Scott AM IsPartOfRelationships: – BibEntity: Dates: – D: 03 M: 03 Text: 2025 Mar 03 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1535-5667 Numbering: – Type: volume Value: 66 – Type: issue Value: 3 Titles: – TitleFull: Journal of nuclear medicine : official publication, Society of Nuclear Medicine Type: main |
| ResultId | 1 |